Rosenheck, R., Swartz, M., McEvoy, J., Stroup, T. S., Davis, S., Keefe, R. S., ... Lieberman, J. (2007). Second-generation antipsychotics: Reviewing the cost-effectiveness component of the CATIE trial. Expert Review of Pharmacoeconomics & Outcomes Research, 7(2), 103-111. DOI: 10.1586/1473718.104.22.168
The cost-effectiveness component of the 18-month CATIE trial of schizophrenia pharmacotherapy (n = 1460) showed that the first-generation antipsychotic perphenazine was US$300-600 per month less expensive than each of four second-generation antipsychotics, and no less effective across multiple measures. We consider whether or not each of eight potential methodological limitations could weaken this conclusion: follow-up rates, study duration, sample characteristics, the choice of outcome measures, exclusion of patients with tardive dyskinesia from assignment to perphenazine, choice of study drugs and doses, reliance on intention-to-treat analysis, and differences in prestudy treatment. We conclude that results of CATIE are robust to these limitations. Perphenazine seems to have been a more representative choice for first-generation antipsychotic comparison treatment than haloperidol.